MARKET

JAGX

JAGX

Jaguar Health Inc
NASDAQ
4.530
-0.170
-3.62%
Pre Market: 4.490 -0.04 -0.88% 07:32 02/07 EST
OPEN
4.820
PREV CLOSE
4.700
HIGH
4.868
LOW
4.500
VOLUME
155
TURNOVER
--
52 WEEK HIGH
61.49
52 WEEK LOW
4.440
MARKET CAP
8.77M
P/E (TTM)
-0.0768
1D
5D
1M
3M
1Y
5Y
Jaguar Health, SynWorld Technologies Terminate Canalevia China Agreement
Jaguar Health, SynWorld Technologies Terminate Canalevia China Agreement
MT Newswires · 6d ago
Jaguar Health Hires Andrew Mulberg as Regulatory Adviser
Jaguar Health Hires Andrew Mulberg as Regulatory Adviser
MT Newswires · 01/30 10:35
Jaguar Health to submit application to begin trial for ultra-rare congenital diarrheal disorder in H1
Seeking Alpha · 01/26 13:57
Jaguar Health Provides Updates Regarding Company's Focus On Rare And Orphan Disease Indications In The U.S. & Europe
Benzinga · 01/26 13:33
Jaguar Health Receives Notice Of Allowance For U.S. Patent Application Titled 'METHODS AND COMPOSITIONS FOR TREATING BILE ACID DIARRHEA, DIARRHEA ASSOCIATED WITH SMALL INTESTINE RESECTION OR GALLBLADDER REMOVAL, AND SHORT BOWEL SYNDROME'
Benzinga · 01/25 16:35
Here's Why Jaguar Health (JAGX) Stock Is Volatile Tuesday
Benzinga · 01/24 20:27
Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher
Benzinga · 01/23 20:03
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga · 01/23 18:44
More
About JAGX
Jaguar Health, Inc. is a commercial stage pharmaceutical company. The Company is focused on developing plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea. The Company operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. Its Canalevia-CA1 is used for chemotherapy-induced diarrhea in dogs. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. Its wholly owned subsidiary is Napo Pharmaceuticals, Inc.

Webull offers kinds of Jaguar Health Inc stock information, including NASDAQ:JAGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAGX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JAGX stock methods without spending real money on the virtual paper trading platform.